LRMR
Price
$4.16
Change
-$0.16 (-3.70%)
Updated
Dec 18, 04:59 PM (EDT)
84 days until earnings call
MDNAF
Price
$1.23
Change
+$0.03 (+2.50%)
Updated
Dec 17 closing price
50 days until earnings call
Ad is loading...

LRMR vs MDNAF

Header iconLRMR vs MDNAF Comparison
Open Charts LRMR vs MDNAFBanner chart's image
Larimar Therapeutics
Price$4.16
Change-$0.16 (-3.70%)
Volume$17.88K
CapitalizationN/A
Medicenna Therapeutics
Price$1.23
Change+$0.03 (+2.50%)
Volume$50.24K
CapitalizationN/A
LRMR vs MDNAF Comparison Chart
Loading...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LRMR vs. MDNAF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LRMR is a Hold and MDNAF is a StrongBuy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (LRMR: $4.32 vs. MDNAF: $1.23)
Brand notoriety: LRMR and MDNAF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LRMR: 275% vs. MDNAF: 37%
Market capitalization -- LRMR: $275.64M vs. MDNAF: $98.28M
LRMR [@Biotechnology] is valued at $275.64M. MDNAF’s [@Biotechnology] market capitalization is $98.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LRMR’s FA Score shows that 1 FA rating(s) are green whileMDNAF’s FA Score has 0 green FA rating(s).

  • LRMR’s FA Score: 1 green, 4 red.
  • MDNAF’s FA Score: 0 green, 5 red.
According to our system of comparison, both LRMR and MDNAF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LRMR’s TA Score shows that 4 TA indicator(s) are bullish while MDNAF’s TA Score has 5 bullish TA indicator(s).

  • LRMR’s TA Score: 4 bullish, 6 bearish.
  • MDNAF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MDNAF is a better buy in the short-term than LRMR.

Price Growth

LRMR (@Biotechnology) experienced а -34.25% price change this week, while MDNAF (@Biotechnology) price change was -6.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

LRMR is expected to report earnings on Mar 12, 2025.

MDNAF is expected to report earnings on Feb 06, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LRMR($276M) has a higher market cap than MDNAF($98.3M). MDNAF YTD gains are higher at: 303.543 vs. LRMR (-5.055).
LRMRMDNAFLRMR / MDNAF
Capitalization276M98.3M281%
EBITDA-73.44MN/A-
Gain YTD-5.055303.543-2%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash204MN/A-
Total Debt5.36MN/A-
FUNDAMENTALS RATINGS
LRMR vs MDNAF: Fundamental Ratings
LRMR
MDNAF
OUTLOOK RATING
1..100
5259
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6538
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (24) in the null industry is somewhat better than the same rating for MDNAF (60). This means that LRMR’s stock grew somewhat faster than MDNAF’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as MDNAF (100). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

LRMR's SMR Rating (100) in the null industry is in the same range as MDNAF (100). This means that LRMR’s stock grew similarly to MDNAF’s over the last 12 months.

MDNAF's Price Growth Rating (38) in the null industry is in the same range as LRMR (65). This means that MDNAF’s stock grew similarly to LRMR’s over the last 12 months.

MDNAF's P/E Growth Rating (100) in the null industry is in the same range as LRMR (100). This means that MDNAF’s stock grew similarly to LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LRMRMDNAF
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 10 days ago
87%
Bullish Trend 22 days ago
87%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
View a ticker or compare two or three
Ad is loading...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GPCR31.480.48
+1.55%
Structure Therapeutics
QCOM157.920.03
+0.02%
QUALCOMM
DERM4.83-0.08
-1.63%
Journey Medical Corp
CGNX36.57-0.90
-2.40%
Cognex Corp
DHIL155.60-4.04
-2.53%
Diamond Hill Investment Group

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with SVRA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then SVRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
-10.56%
SVRA - LRMR
40%
Loosely correlated
-1.23%
TRDA - LRMR
38%
Loosely correlated
+2.44%
MLYS - LRMR
36%
Loosely correlated
+1.56%
ABSI - LRMR
36%
Loosely correlated
-13.05%
IDYA - LRMR
36%
Loosely correlated
+1.07%
More

MDNAF and

Correlation & Price change

A.I.dvisor tells us that MDNAF and LRMR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDNAF and LRMR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNAF
1D Price
Change %
MDNAF100%
+2.50%
LRMR - MDNAF
25%
Poorly correlated
-10.56%
VIR - MDNAF
25%
Poorly correlated
-2.78%
STOK - MDNAF
23%
Poorly correlated
-1.14%
CGEM - MDNAF
23%
Poorly correlated
-2.63%
PTCT - MDNAF
22%
Poorly correlated
-3.27%
More